Characteristics of the IGHV3-21-expressing CLL patients belonging to the common-HCDR3 subset
. | Fra1 . | Fra3 . | Gre1 . | Ita1 . | Ita3 . | Ita4 . | Spa1 . |
|---|---|---|---|---|---|---|---|
| No. of cases | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Age, y | 69 | 46 | 56 | 72 | 69 | 91 | 90 |
| Sex | F | M | M | M | M | F | F |
| IGHJ gene | IGHJ6 | IGHJ6 | IGHJ6 | IGHJ6 | IGHJ6 | IGHJ6 | IGHJ6 |
| IGHV homology, % | 94.9 | 98.3 | 98.0 | 96.3 | 98.6 | 98.3 | 96.9 |
| LC | Vλ2-14 | IGKV3-15 | Vλ2-14 | Vλ2-14 | Vλ2-14 | Vλ2-14 | Vλ2-14 |
| IGJ LC gene | IGLJ3 | IGKJ1 | IGLJ3 | IGLJ3 | IGLJ3 | IGLJ3 | IGLJ3 |
| IGV LC homology, % | 99.7 | 100 | 100 | 99 | 98.6 | 98.3 | 99.7 |
| CD38, % | 7 | 47 | 7.7 | 99 | 53 | 99 | 46 |
| Stage at diagnosis | B | B | B | B | C | A | C |
| Progression | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Need for treatment | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| CLL-related death | No | Yes | No | Yes | No | No | Yes |
. | Fra1 . | Fra3 . | Gre1 . | Ita1 . | Ita3 . | Ita4 . | Spa1 . |
|---|---|---|---|---|---|---|---|
| No. of cases | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Age, y | 69 | 46 | 56 | 72 | 69 | 91 | 90 |
| Sex | F | M | M | M | M | F | F |
| IGHJ gene | IGHJ6 | IGHJ6 | IGHJ6 | IGHJ6 | IGHJ6 | IGHJ6 | IGHJ6 |
| IGHV homology, % | 94.9 | 98.3 | 98.0 | 96.3 | 98.6 | 98.3 | 96.9 |
| LC | Vλ2-14 | IGKV3-15 | Vλ2-14 | Vλ2-14 | Vλ2-14 | Vλ2-14 | Vλ2-14 |
| IGJ LC gene | IGLJ3 | IGKJ1 | IGLJ3 | IGLJ3 | IGLJ3 | IGLJ3 | IGLJ3 |
| IGV LC homology, % | 99.7 | 100 | 100 | 99 | 98.6 | 98.3 | 99.7 |
| CD38, % | 7 | 47 | 7.7 | 99 | 53 | 99 | 46 |
| Stage at diagnosis | B | B | B | B | C | A | C |
| Progression | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Need for treatment | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| CLL-related death | No | Yes | No | Yes | No | No | Yes |
Fra indicates France; Gre, Greece; Ita, Italy; Spa, Spain.